Cargando…
Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model
Brain metastases are common in patients with non-small-cell lung cancer (NSCLC). The efficacy of bevacizumab, an anti-vascular endothelial growth factor (VEGF) humanized antibody, has been demonstrated in patients with nonsquamous NSCLC. We established a transplantable NSCLC cell line (Nluc-H1915) t...
Autores principales: | Masuda, Chinami, Sugimoto, Masamichi, Wakita, Daiko, Monnai, Makoto, Ishimaru, Chisako, Nakamura, Ryo, Kinoshita, Mari, Yorozu, Keigo, Kurasawa, Mitsue, Kondoh, Osamu, Yamamoto, Kaname |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007905/ https://www.ncbi.nlm.nih.gov/pubmed/31768815 http://dx.doi.org/10.1007/s10585-019-10008-z |
Ejemplares similares
-
PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8(+) T cells in hematogenous metastasis model with lymphocyte infusion
por: Masuda, Chinami, et al.
Publicado: (2021) -
Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies
por: Iwai, Toshiki, et al.
Publicado: (2018) -
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017) -
Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model
por: Ishikura, Nobuyuki, et al.
Publicado: (2019) -
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
por: Iwai, Toshiki, et al.
Publicado: (2016)